Evidence map›Paper›PMID 38592294›Full record

ArticleJournal of clinical medicine2024

Factors Associated with Survival and Discontinuation of Anti-Malarial Agents in Systemic Lupus Erythematosus: Results from a Tertiary Swedish Referral Centre.

Tomas Walhelm, Lina Wirestam, Yvonne Enman, Ioannis Parodis, Christopher Sjöwall

Abstract read
In one paragraph

Article in Journal of clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Tomas WalhelmDivision of Inflammation and Infection/Rheumatology, Department of Biomedical and Clinical Sciences, Linköping University, SE-581 83 Linköping, Sweden.ORCID 0000-0003-4590-4866
Lina WirestamDivision of Inflammation and Infection/Rheumatology, Department of Biomedical and Clinical Sciences, Linköping University, SE-581 83 Linköping, Sweden.ORCID 0000-0003-3687-8344
Yvonne EnmanDivision of Rheumatology, Department of Medicine Solna, Karolinska Institutet, SE-171 77 Stockholm, Sweden.
Ioannis ParodisDivision of Rheumatology, Department of Medicine Solna, Karolinska Institutet, SE-171 77 Stockholm, Sweden.ORCID 0000-0002-4875-5395
Christopher SjöwallDivision of Inflammation and Infection/Rheumatology, Department of Biomedical and Clinical Sciences, Linköping University, SE-581 83 Linköping, Sweden.ORCID 0000-0003-0900-2048

Funding

Gustafsson Foundation 2023-36, 2021-26Karolinska Institutet 2021King Gustaf V and Queen Victoria's Freemasons Foundation 2021King Gustaf V:s 80-year anniversary Foundation FAI-2020-0663, FAI-2020-0741Nyckelfonden OLL-974804Professor Nanna Svartz Foundation 2021-00436Region Östergötland RÖ-960604Region Stockholm FoUI-955483Swedish Research Council 2023-02256Swedish Rheumatism Association R-939149, R-969696Swedish Society of Medicine SLS-974449
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

antimalarialschloroquinedrug survivalhydroxychloroquinesystemic lupus erythematosus

Identifiers

PMID38592294
PMCPMC10934232

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.